Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies
暂无分享,去创建一个
Ming‐Lung Yu | M. Yeh | Chung‐Feng Huang | Ching-I. Huang | C. Dai | M. Hsieh | Shinn‐Chern Chen | Jee-Fu Huang | W. Chuang | Ta-Ya Lin | M. Yu | Ching-I Huang | Jee‐Fu Huang
[1] N. Giama,et al. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[2] F. Foufelle,et al. Steatosis and NASH in type 2 diabetes. , 2017, Biochimie.
[3] Ramesh Kumar,et al. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications , 2017, Journal of clinical and translational hepatology.
[4] Ming‐Lung Yu,et al. Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients , 2017, PloS one.
[5] L. Adams,et al. International Journal of Molecular Sciences the Natural Course of Non-alcoholic Fatty Liver Disease , 2022 .
[6] L. Henry,et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 , 2015, Hepatology.
[7] Shyi-Jang Shin,et al. Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients , 2015, PloS one.
[8] E. Bjornsson,et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.
[9] A. Burt,et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.
[10] Mats Fredrikson,et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.
[11] Zhen Wang,et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] Aijaz Ahmed,et al. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.
[13] Aijaz Ahmed,et al. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. , 2014, World journal of hepatology.
[14] T. Tung,et al. Relationship between obesity, metabolic syndrome, and nonalcoholic fatty liver disease in the elderly agricultural and fishing population of Taiwan , 2014, Clinical interventions in aging.
[15] R. DeFronzo,et al. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.
[16] K. Cusi,et al. Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[17] A. Baranova,et al. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.
[18] H. Makhlouf,et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality , 2011, Hepatology.
[19] Vincent Wai-Sun Wong,et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.
[20] Greger Lindberg,et al. Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.
[21] J. Girard,et al. Role of ChREBP in hepatic steatosis and insulin resistance , 2008, FEBS letters.
[22] G. Targher,et al. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. , 2007, Atherosclerosis.
[23] Chien-Hua Chen,et al. Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in an Adult Population of Taiwan: Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese Adults , 2006, Journal of clinical gastroenterology.
[24] E. Bugianesi,et al. Steatosis and hepatocellular carcinoma risk. , 2005, European review for medical and pharmacological sciences.
[25] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[26] C. Nishida,et al. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.
[27] G. Marchesini,et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.
[28] P. Thuluvath,et al. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.
[29] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[30] S. Caldwell,et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.